NATCOPHARM · Healthcare
NATCO Pharma Ltd. reported revenue of ₹759 cr for October to December 2023, — on the year and −26.4% on the quarter.
Operating profit (EBITDA) was ₹268 cr, a margin of 35.3%, — on the year and −911 bps on the quarter.
Net profit was ₹213 cr, — on the year and −42.3% on the quarter, with earnings per share of ₹10.84.
Written from the quarterly statements. The filing read adds the balance sheet and cash flow, the auditor's review, segment results, one-off items line by line and what management said on the call.
No check fired. That is a statement about the checks below, not a verdict on the company.
Could not run on this quarter: Headline vs core profit, Exceptional items that recur, Operating margin on the year, Depreciation falling, Finance cost rising, Swing to loss or profit, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery, When the results were filed. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
| Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,031 cr | ₹759 cr | ₹1,068 cr | ₹1,363 cr | ₹1,371 cr | ₹475 cr | ₹1,221 cr | ₹1,329 cr | ₹1,363 cr | ₹647 cr | ₹739 cr | ₹735 cr |
| YoY | — | — | — | +20% | +33% | −37% | +14% | −2% | −1% | +36% | −39% | −45% |
| EBITDA margin | 44.4% | 35.3% | 46.5% | 59.1% | 58.6% | 8.2% | 44.9% | 43.0% | 42.5% | 24.6% | 17.3% | 25.3% |
| Other income, % of PBT | 7% | 14% | 9% | 6% | 8% | 107% | 13% | 11% | 16% | 36% | 54% | 32% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | 16% | 17% | 19% | 17% | 17% | 19% | 20% | 16% | 16% | 13% | — | 34% |
| Net profit | ₹369 cr | ₹213 cr | ₹386 cr | ₹668 cr | ₹676 cr | ₹132 cr | ₹406 cr | ₹480 cr | ₹518 cr | ₹151 cr | ₹269 cr | ₹206 cr |
| YoY | — | — | — | +59% | +83% | −38% | +5% | −28% | −23% | +14% | −34% | −57% |
| Core profit YoY | — | — | — | +57% | +83% | −105% | +1% | −33% | −32% | — | −85% | −75% |
| EPS | ₹18.81 | ₹10.84 | ₹19.69 | ₹34.07 | ₹34.52 | ₹6.78 | ₹20.72 | ₹24.50 | ₹26.42 | ₹7.72 | ₹13.65 | ₹10.52 |
| Flags | · | · | · | ✓ | ✓ | 2 | ✓ | 1 | 1 | ✓ | 3 | 2 |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
NATCO Pharma Ltd. reported revenue of ₹759 cr (— on the year) and net profit of ₹213 cr (— on the year) for October to December 2023.
None of the 2 checks that could run raised a question.
No. FinMinutes reports what was filed and the questions the numbers raise. It does not recommend buying, selling or holding any security.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.